These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26287748)

  • 1. New DTCA Guidance--Enough to Empower Consumers?
    Robertson CT
    N Engl J Med; 2015 Sep; 373(12):1085-7. PubMed ID: 26287748
    [No Abstract]   [Full Text] [Related]  

  • 2. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 3. Direct-to-consumer advertising of prescription drugs.
    Frosch DL; Grande D
    LDI Issue Brief; 2010; 15(3):1-4. PubMed ID: 20469541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To ban or not to ban--that is the question: the constitutionality of a moratorium on consumer drug advertising.
    Schwartz MI
    Food Drug Law J; 2008; 63(1):1-33. PubMed ID: 18561453
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 6. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct-to-consumer advertising of drugs.
    Weinmeyer R
    Virtual Mentor; 2013 Nov; 15(11):954-8. PubMed ID: 24257087
    [No Abstract]   [Full Text] [Related]  

  • 8. US Congress to consider limits on DTCA.
    Guthrie P
    CMAJ; 2007 May; 176(10):1404. PubMed ID: 17485685
    [No Abstract]   [Full Text] [Related]  

  • 9. Ensuring that consumers receive appropriate information from drug ads: what is the FDA's role?
    Waxman HA
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-256-8. PubMed ID: 15452002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 11. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug risks and free speech--can Congress ban consumer drug ads?
    Shuchman M
    N Engl J Med; 2007 May; 356(22):2236-9. PubMed ID: 17476002
    [No Abstract]   [Full Text] [Related]  

  • 13. Direct-to-consumer prescription drug advertising.
    Terzian TV
    Am J Law Med; 1999; 25(1):149-67. PubMed ID: 10207573
    [No Abstract]   [Full Text] [Related]  

  • 14. The federal regulation of prescription drug advertising and promotion.
    Kessler DA; Pines WL
    JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health related claims, the market for information, and the first amendment.
    Beales JH
    Health Matrix Clevel; 2011; 21(1):7-30. PubMed ID: 21847896
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA regulation of prescription drug advertising.
    Peck CC; Rheinstein PH
    JAMA; 1990 Nov; 264(18):2424-5. PubMed ID: 2232001
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 19. Legislative and non-legislative regulations concerning Rx drug advertisement in the European Union and the United States--comparative analysis.
    Czerw A; Religioni U
    Acta Pol Pharm; 2012; 69(4):779-87. PubMed ID: 22876622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to safety data--stockholders versus prescribers.
    Pfeffer MA; Bowler MB
    N Engl J Med; 2011 Jul; 365(1):1-3. PubMed ID: 21714642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.